MUMBAI, India and WALTHAM, Mass., March 9, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE ...

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio ...

Sun Pharmaceutical Industries Ltd. has announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company, in a $355 million cash deal.

March 10 (Reuters) - India's Sun Pharmaceutical Industries (SUN.NS), opens new tab said on Monday it will acquire Checkpoint Therapeutics (CKPT.O), opens new tab, a U.S.-based immunotherapy and ...

Sun Pharma is set to acquire Checkpoint Therapeutics for $355 million, enhancing its specialty portfolio with UNLOXCYT, an FDA-approved treatment for advanced skin cancer. This acquisition aims to ...

Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology treatments, for an aggregate upfront price of $355m.

Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of $355 million, or $4.10 per share, the companies said Sunday. With Unloxcyt, an FDA-approved PD-L1 therapy for ...

I write about Asia's richest, fast-growing businesses, and startups. Sun Pharmaceutical Industries Ltd. signage is displayed outside the company's corporate office in ... [+] Mumbai. Sun ...

Sun Pharmaceutical Industries Ltd and Nasdaq-listed Checkpoint Therapeutics, Inc. have announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an ...

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma. Sun Pharma announced ...

MUMBAI, March 1 (Reuters) - India's largest drugmaker by revenue Sun Pharmaceutical (SUN.NS), opens new tab is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next ...